Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain.
To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events. Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam. A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21% of lornoxicam-treated patients, with GI events the most frequent (14 vs 8% with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95% CI: 0.64-0.96]; p = 0.017). Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.